Akebia Therapeutics regaining compliance with Nasdaq's minimum bid price requirement is a positive development for the company, as it ensures its stock will continue to be listed and traded on the Nasdaq Capital Market. This news may boost investor confidence and potentially lead to a short-term increase in the stock price.